Considerations in the management of steroid-dependent Crohn's disease

Gastroenterology

Volumn 125, Issue 3, 2003, Pages 906-910

  Hanauer, Stephen B ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; STEROID;

ABDOMINAL PAIN; ADULT; CASE REPORT; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE; CORTICOSTEROID THERAPY; CROHN DISEASE; DIARRHEA; FEMALE; FEVER; HUMAN; PRIORITY JOURNAL; REMISSION; REVIEW; TREATMENT PLANNING;

EID: 0041322997     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(03)01129-6     Document Type: Article

References (32)

1. Hanauer SB. Review articles: drug therapy: inflammatory bowel disease. N Engl J Med 1996;334:841-848.
2. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121:255-260.
3. Yang YX, Lichtenstein GR. Corticosteroids in Crohn's disease. Am J Gastroenterol 2002;97:803-823.
4. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994;35:360-362.
5. Modigliani R, Colombel JF, Dupas JL, Dapoigny M, Costil V, Veyrac M, Duclos B, Soule JC, Gendre JP, Galmiche JP, Danne O, Cadiot G, Lamouliatte H, Belaiche J, Mary JY. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1996;110:688-693.
6. Lofberg R, Rutgeerts P, Malchow H, Lamers C, Danielsson A, Olaison G, Jewell D, Ostergaard Thomsen O, Lorenz-Meyer H, Goebell H, Hodgson H, Persson T, Seidegard C. Budesonide prolongs time to relapse in ifeal and ileocaecal Crohn's disease. A placebo controlled one-year study. Gut 1996;39:82-86.
7. Miner PB Jr. Factors influencing the relapse of patients with inflammatory bowel disease. Am J Gastroenterol 1997;92(12 Suppl):1S-4S.
8. Cosnes J, Carbonnel F, Beaugerie L, Le Quintrec Y, Gendre JP. Effects of cigarette smoking on the long-term course of Crohn's disease [see comments]. Gastroenterology 1996;110:424-431.
9. Silverstein MD, Loftus EV, Sandborn WJ, Tremaine WJ, Feagan BG, Nietert PJ, Harmsen WS, Zinsmeister AR. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 1999;117:49-57.
10. Thirlby RC, Sobrino MA, Randall JB. The long-term benefit of surgery on health-related quality of life in patients with inflammatory bowel disease. Arch Surg 2001;136:521-527.
11. Achkar JP, Hanauer SB. Medical therapy to reduce postoperative Crohn's disease recurrence. Am J Gastroenterol 2000;95:1139-1146.
12. Ewe K, Press AG, Singe CC, Stufler M, Ueberschaer B, Hommel G, Meyer zum Buschenfelde KH. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease [see comments]. Gastroenterology 1993;105:367-372.
13. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995;37:674-678.
14. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease [in process citation]. Gastroenterology 2000;119:895-902.
15. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980;302:981-987.
16. Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Gillies R, Hopkins M, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators [see comments]. N Engl J Med 1995;332:292-297.
17. Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease [see comments]. Ann Intern Med 1989;110:353-356.
18. Chong RY, Hanauer SB, Cohen RD. Efficacy of parenteral methotrexate in refractory Crohn's disease. Aliment Pharmacol Ther 2001;15:35-44.
19. Lemann M, Chamiot-Prieur C, Mesnard B, Halphen M, Messing B, Rambaud JC, Gendre JP, Colombel JF, Modigliani R. Methotrexate for the treatment of refractory Crohn's disease. Aliment Pharmacol Ther 1996;10:309-314.
20. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-1549.
21. Cortot A, Colombel JF, Rutgeerts P, Lauritsen K, Malchow H, Hamling J, Winter T, Van Gossum A, Persson T, Pettersson E. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease. Gut 2001;48:186-190.
22. Kane SV, Schoenfeld P, Sandborn WJ, Tremaine W, Hofer T, Feagan BG. Systematic review: the effectiveness of budesonide therapy for Crohn's disease. Aliment Pharmacol Ther 2002;16:1509-1517.
23. Feagan BG, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Koval J, Wong CJ, Hopkins M, Hanauer SB, McDonald JW. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators [see comments]. N Engl J Med 2000;342:1627-1632.
24. Polifka JE, Friedman JM. Teratogen update: azathioprine and 6-mercaptopurine. Teratology 2002;65:240-261.
25. Sandborn WJ. Azathioprine: state of the art in inflammatory bowel disease. Scand J Gastroenterol 1998;225(Suppl):92-99.
26. Sandborn WJ. Rational dosing of azathioprine and 6-mercaptopurine. Gut 2001;48:591-592.
27. Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002;122:904-915.
28. Colonna T, Korelitz BI. The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease. Am J Gastroenterol 1994;89:362-366.
29. Bouhnik Y, Lemann M, Mary JY, Scemama G, Tai R, Matuchansky C, Modigliani R, Rambaud JC. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine [see comments]. Lancet 1996;347:215-219.
30. Lemann M, et al. Randomized, double-blind, placebo-controlled, multicenter, azathioprine withdrawal trial in Crohn's disease (abstr). Gastroenterology 2002;122:174A.
31. Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol 2002;97:2962-2972.
32. Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol 2000;95:3469-3477.